Why Medtronic Plc (MDT) stock moved
Medtronic Plc (MDT) shares fell 0.6% to $94.79 as of October 27, 2026, a slight decline from the prior close of $95.41. BestStocks flagged the session as a major change for MDT. Below, we break down what changed for MDT, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
MDT fell 0.6% to $94.79
Medtronic announced positive real-world registry results for its Sphere-9™ catheter and PulseSelect™ PFA System at the APHRS 2026 conference (PR Newswire), driving a +2.72% intraday gain to $95.56. Volume remains below average at 0.24x expected levels for this time of session, suggesting limited participation in the move so far. MDT earnings announcement on 2026-11-17 (date pending confirmation), with consensus EPS estimate of $1.34; watch for guidance tied to Sphere-9 and PulseSelect adoption rates.
What it means for Medtronic Plc investors
For Medtronic Plc investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Positive price momentum; Medtronic plc (MDT) moved +5.04% from $79.20 to $83.19 on 2026-07-02. Weighing against that: Negative session, down 0.6%; Medtronic plc (MDT) moved -5.11% from $83.57 to $79.30 on 2026-07-14. Wall Street's consensus price target sits at $97.73, implying +3.1% upside from $94.79. BestStocks rates the overall signal quality weak (33/100). With earnings roughly 21 days out, the next report is the most likely near-term test of the move.
MDT price reaction
MDT last traded at $94.79, down $0.62 (-0.65%) from the previous close of $95.41. The session traded on 0.5× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $85.51 and $96.59, and it currently sits about 84% of the way up that band.
Bullish and bearish analyst opinions on Medtronic Plc (MDT)
The consensus analyst price target on Medtronic Plc (MDT) is $97.73, 3.1% above the recent $94.79. Over the past 90 days analysts logged 0 upgrades, 14 maintains, and 0 downgrades. Here is how the bullish and bearish cases on MDT line up.
The bullish case
- Wall Street's consensus price target of $97.73 implies +3.1% upside from $94.79.
- The Street's most bullish target is $115.00 (+21.3%).
- Positive price momentum.
- Medtronic plc (MDT) moved +5.04% from $79.20 to $83.19 on 2026-07-02.
The bearish case
- The most bearish analyst target is $83.00 (-12.4%).
- Negative session, down 0.6%.
- Medtronic plc (MDT) moved -5.11% from $83.57 to $79.30 on 2026-07-14.
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Oct 26, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for MDT
Frequently asked questions about MDT
Why did Medtronic Plc (MDT) stock move?
MDT fell 0.6% to $94.79. The move coincided with the context summarized above, though no single company-specific catalyst was independently confirmed.
How much did MDT stock fall?
MDT lost 0.65% ($0.62) versus the prior close of $95.41, last trading at $94.79 on 0.5× average volume.
When is Medtronic Plc's next earnings date?
MDT's next earnings report is estimated for 2026-11-17 — about 21 days away.
What is the analyst price target for MDT?
The consensus analyst price target for MDT is $97.73, about 3.1% above the current $94.79. Over the past 90 days, analysts recorded 0 upgrades, 14 maintains, and 0 downgrades.
How BestStocks tracks MDT
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared MDT-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for MDT, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of October 27, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.